Evidence map›Paper›PMID 25927611›Full record

ArticlePloS one2015

Modulation of bleomycin-induced lung fibrosis by pegylated hyaluronidase and dopamine receptor antagonist in mice.

Evgenii Germanovich Skurikhin, Olga Victorovna Pershina, Alena Mikhaylovna Reztsova, Natalia Nikolaevna Ermakova, Ekaterina Sergeevna Khmelevskaya, Vycheslav Andreevich Krupin, Inna Ernestovna Stepanova, Andrew Vladimirovich Artamonov, Andrew Alexandrovich Bekarev, Pavel Gennadjevich Madonov and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Dopamine receptors and organ fibrosis.Biochemistry and biophysics reports · 2025
    Review
  3. The effect of adrenalectomy on bleomycin-induced pulmonary fibrosis in mice.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis.International journal of molecular sciences · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Hyaluronan as a therapeutic target in human diseases.Advanced drug delivery reviews · 2016
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Evgenii Germanovich SkurikhinDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Olga Victorovna PershinaDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Alena Mikhaylovna ReztsovaDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Natalia Nikolaevna ErmakovaDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Ekaterina Sergeevna KhmelevskayaDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Vycheslav Andreevich KrupinDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Inna Ernestovna StepanovaDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Andrew Vladimirovich ArtamonovLimited Liability Company «Scientific Future Management», Novosibirsk, Russia.
Andrew Alexandrovich BekarevLimited Liability Company «Scientific Future Management», Novosibirsk, Russia.
Pavel Gennadjevich MadonovLimited Liability Company «Scientific Future Management», Novosibirsk, Russia.
Alexander Mikhaylovich DygaiDepartment of Pathophysiology and Regenerative Medicine, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, Tomsk, Russia.
Research Institute of Pharmacology and Regenerative Medicine named ED Goldberg · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronidases are groups of enzymes that degrade hyaluronic acid (HA). To stop enzymatic hydrolysis we modified testicular hyaluronidase (HYAL) by activated polyethylene oxide with the help of electron-beam synthesis. As a result we received pegylated hyaluronidase (pegHYAL). Spiperone is a selective D2 dopamine receptor antagonist. It was demonstrated on the model of a single bleomycin damage of alveolar epithelium that during the inflammatory phase monotherapy by pegHYAL or spiperone reduced the populations of hematopoietic stem /progenitor cells in the lung parenchyma. PegHYAL also reduced the levels of transforming growth factor (TGF)-β, interleukin (IL)-1β, tumor necrosis factor (TNF)-α in the serum and lungs, while spiperone reduced the level of the serum IL-1β. Polytherapy by spiperone and pegHYAL caused the increase of the quantity of hematopoietic stem/ progenitor cells in the lungs. Such an influx of blood cell precursors was observed on the background of considerable fall level of TGF-β and the increase level of TNF-α in the serum and lungs. These results show pegHYAL reduced the bleomycin-induced fibrosis reaction (production and accumulation of collagen) in the lung parenchyma. This effect was observed at a single and repetitive bleomycin damage of alveolar epithelium, the antifibrotic activity of pegHYAL surpassing the activity of testicular HYAL. The antifibrotic effect of pegHYAL is enhanced by an additional instillation of spiperone. Therapy by pegHYAL causes the flow of CD31‒ CD34‒ CD45‒ CD44+ CD73+ CD90+ CD106+-cells into the fibrous lungs. These cells are incapable of differentiating into fibroblast cells. Spiperone instillation separately or together with pegHYAL reduced the MSC-like cells considerably. These data enable us to assume, that pegHYAL is a new and promising instrument both for preventive and therapy of toxic pneumofibrosis. The blockage of D2 dopamine receptors with the following change of hyaluronan matrix can be considered as a new strategy in treatment of pneumofibrosis.

Indexed as

AnimalsBleomycinDopamine AntagonistsEnzyme-Linked Immunosorbent AssayFlow CytometryHyaluronoglucosaminidaseMaleMiceMice, Inbred C57BLPulmonary FibrosisSpiperoneBleomycinDopamine AntagonistsHyaluronoglucosaminidaseSpiperone

Identifiers

PMID25927611
PMCPMC4415936
OpenAlexW2076919119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.